QQ客服 官方微博 反馈留言

	Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
	Gu, Xiaohua; Zhang, Qiang; Chu, Yun-Bo; Zhao, Yi-Yang; Zhang, Yan-Jun; Kuo, David; Su, Betty; Wu, Bin
刊名	LUNG CANCER
	2019
卷号	127
关键词	Afatinib EGFR mutation Cost-effectiveness Non-small cell lung cancer
ISSN号	0169-5002
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3630210
专题	上海中医药大学
推荐引用方式 GB/T 7714	Gu, Xiaohua,Zhang, Qiang,Chu, Yun-Bo,et al. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China[J]. LUNG CANCER,2019,127.
APA	Gu, Xiaohua.,Zhang, Qiang.,Chu, Yun-Bo.,Zhao, Yi-Yang.,Zhang, Yan-Jun.,...&Wu, Bin.(2019).Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.LUNG CANCER,127.
MLA	Gu, Xiaohua,et al."Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China".LUNG CANCER 127(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。